Analysis of IC50s for growth inhibition across multiple cell lines shows that when compared to KRAS-wild type cells, KRAS-mutant cell lines are most sensitive to MEK inhibitors compared to inhibitors of other cancer-associated pathways8. The gene discussed is KRAS; the disease is cancer.